Programme

This one-day conference will include a mixture of plenary sessions, oral presentations and posters and will bring together leading international experts, clinicians, patient partners and early career researchers to engage with the latest advances in the field of PROMs research and implementation. 

Please save the date and join us on the Wednesday 20th June 2018.  

Detailed programme now available to download. (updated 08.06.18)

Plenary Speakers

We are pleased to confirm the following Plenary Speakers, Dr Daniel O'Connor, MHRA, Dr Tessa Richards, BMJ and Dr Kirstie Haywood, Warwick University.

Dr Daniel O'Connor

Daniel O'Connor x 200Daniel is a Leicester medical graduate with a background in cancer research, histopathology and oncology. His PhD in the field of tumour suppressor genes was awarded from Imperial College London and he holds an MSc in Oncology from the Institute of Cancer Research. He completed higher medical training in the UK in Pharmaceutical Medicine. 
He joined the Medicines and Healthcare products Regulatory Agency (MHRA) as a Medical Assessor in 2006 from a clinical lecturer post at UCL/UCH/Ludwig Institute for Cancer Research. He works in the licensing division of the MHRA. He is the UK representative on the Committee for Orphan Medicinal Products (COMP), COMP representative on the EMA’s Scientific Advice Working Party (SAWP) and the Patient and Consumer Working Party (PCWP), and observer on the EMA’s Oncology Working Party. He is editor author of the first edition Oxford Specialist Handbook of Pharmaceutical Medicine and he is on the editorial board of the journal Expert Opinion on Orphan Drugs.

 

Dr Tessa Richards 

Tessa Richardsx200Dr Tessa Richards is a senior editor at the BMJ and leads the BMJs patient partnership initiative. She worked  as a general physician, rheumatologist and  a GP  before joining the BMJ editorial staff.  Here she has led the journals  GP, Education and Analysis sections,  and established  the Overdiagnosis/Too Much Medicine series , one on High Integrity Health. She is a member of the Royal College of Physicians, a BMJ columnist and writes regularly on patient perspectives. Series she has edited include ones on Partnering with Patients, and Patient Centred Care.  She lives with stage IV cancer and two long term conditions , and  is   a carer for  close family members with rheumatoid arthritis, dementia, and blindness.

 

Dr Kirstie Haywood

Kirstie-Haywoodx200Kirstie leads the Patient Reported Outcomes (PRO) Research programme at Warwick Medical School. Her research interests include health-related quality of life (HRQoL), measurement science and patient-reported outcomes research in clinical practice, research and health policy. The work programme covers a wide range of conditions, populations and settings including long-term conditions (e.g., a range of musculoskeletal/rheumatological conditions, chronic fatigue), recovery from episodes of ill-health or injury (e.g., cardiac arrest, traumatic hip fracture); using / evaluating / developing PRO measures (PROMs) for use in research, clinical practice, disease registries and audit (e.g., maternity; exercise adherence; axial spondyloarthropathies); and developing approaches to effective patient and public involvement (PPI) in HRQoL and PRO research.

Recent work has included the development of Core Outcome Sets (COS) for cardiac arrest (COSCA), headache (COSH), and fragility hip fracture (WHiTE). The International COSCA initiative is endorsed by both the European Resuscitation Council (ERC) and the International Liaison Committee on Resuscitation (ILCOR). The WHiTE COS has been incorporated into England’s Hip Fracture Audit. She has contributed to the European Resuscitation Registry for Cardiac Arrests (EuReCa) stakeholder group, raising the importance of capturing the voice of survivors. She was an invited member of the ERC 2015 Resuscitation Guidelines writing group (Ethics of Resuscitation; European Survey of Resuscitation practice) and is a member of the American Heart Association (AHA) writing group tasked with developing of a ‘Statement of Survival after Cardiac Arrest’. Kirstie was an expert member of England’s DoH PROM Stakeholder Reference Group (2009-2013) and a European working group contributing to a policy debate on the role of PROs in healthcare (‘The Value of Health: Healthcare Outcomes as Drivers for Sustainable Health Systems’ (FIPRA funded)). Until recently, Kirstie co-chaired the Clinical Practice Special Interest Group (SIG) of the International Society of Quality of Life research (ISOQOL). She is a founding member and co-chair of the ISOQOL Patient Engagement SIG and member of the Trials Taskforce and working group.

Programme Overview

 09:30  Registration and refreshments  
 10:00  Welcome from Professor Melanie Calvert and Gary Price
 10:15  Plenary Session 1 
 Dr Dan O'Connor, MHRA, PROs from the regulatory perspective
 Dr Tessa Richards, BMJ
 10:45  Parallel session 1  
  Great Hall 
Minimising PRO waste
WG05 
PROS in chronic disease/different settings
WG12 
Cutting edge methods
 11:45  Refreshments Poster Viewing  
 12:00  Parallel session 2  
  Great Hall 
Pushing boundaries
WG05 
Economic evaluation
WG12 
Digital Capture of PROs
 13:00  Lunch and Poster Viewing  
 14:00  Parallel session 3  
  Great Hall 
Digital Capture of PROs
WG05 
Cutting edge methods
WG12 
PROs in chronic disease/different settings
 15:00  Refreshments and Poster Viewing  
 15:30  Plenary 2  
 Dr Kirstie Haywood, Warwick Medical School
 16:00  General discussion    
 16:30  Close    

Download a copy of the detailed programme. (updated 08.06.18)

  Endorsed by the International Society for Quality of Life Research
isoqol-300

Please be aware that photographs will be taken at this event for promotional use. If you have any concerns about this please let the event organiser know.